Compare

Grace Therapeutics, Inc. vs Context Therapeutics Inc. vs Spero Therapeutics, Inc. vs Werewolf Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Grace Therapeutics, Inc. GRCE	Context Therapeutics Inc. CNTX	Spero Therapeutics, Inc. SPRO	Werewolf Therapeutics, Inc. HOWL
Year ended	2026-03-31	2025-12-31	2025-12-31	2025-12-31
Revenue	n/a	n/a	$66.80M	n/a
Revenue growth (YoY)	n/a	n/a	+39.2%	n/a
Gross margin	n/a	n/a	n/a	n/a
Operating margin	n/a	n/a	9.5%	n/a
Net margin	n/a	n/a	12.8%	n/a
Net income	-$7.79M	-$36.12M	$8.57M	-$60.82M
EPS (Diluted)	-$0.47	-$0.38	$0.15	-$1.33
Operating cash flow	-$8.87M	-$26.39M	-$12.62M	-$60.29M
Free cash flow	n/a	-$26.42M	n/a	-$60.29M
Cash & equivalents	$16.98M	$66.00M	$40.27M	$57.05M
Total assets	$66.65M	$68.49M	$68.92M	$69.40M
Total liabilities	$2.76M	$8.02M	$9.90M	$44.59M
Shareholders' equity	$63.90M	$60.47M	$59.02M	$24.80M
Return on year-end equity	-12.2%	-59.7%	14.5%	-245.2%
Shares outstanding	n/a	91.88M	56.41M	48.60M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Grace Therapeutics, Inc.	Context Therapeutics Inc.	Spero Therapeutics, Inc.	Werewolf Therapeutics, Inc.
Latest	$100.00M Ended 2022-03-31	n/a	$66.80M Ended 2025-12-31	n/a
1 year earlier	n/a	n/a	$47.98M Ended 2024-12-31	n/a
2 years earlier	n/a	n/a	$103.78M Ended 2023-12-31	n/a
3 years earlier	n/a	n/a	$53.51M Ended 2022-12-31	n/a
4 years earlier	n/a	n/a	$18.26M Ended 2021-12-31	n/a